Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.

Veschi V, Mangiapane LR, Nicotra A, Di Franco S, Scavo E, Apuzzo T, Sardina DS, Fiori M, Benfante A, Colorito ML, Cocorullo G, Giuliante F, Cipolla C, Pistone G, Bongiorno MR, Rizzo A, Tate CM, Wu X, Rowlinson S, Stancato LF, Todaro M, De Maria R, Stassi G.

Oncogene. 2019 Oct 7. doi: 10.1038/s41388-019-1047-4. [Epub ahead of print]


Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.

Lowery CD, Blosser W, Dowless M, Renschler M, Perez LV, Stephens J, Pytowski B, Wasserstrom H, Stancato LF, Falcon B.

Oncotarget. 2019 Sep 17;10(53):5523-5533. doi: 10.18632/oncotarget.27148. eCollection 2019 Sep 17.


Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.


Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.


Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management.

Gaebler M, Silvestri A, Haybaeck J, Reichardt P, Lowery CD, Stancato LF, Zybarth G, Regenbrecht CRA.

Front Oncol. 2017 Sep 11;7:203. doi: 10.3389/fonc.2017.00203. eCollection 2017. Review.


The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.

Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF.

Clin Cancer Res. 2017 Aug 1;23(15):4354-4363. doi: 10.1158/1078-0432.CCR-16-2876. Epub 2017 Mar 7.


LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.

Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002.


Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.

Peng SB, Zhang X, Paul D, Kays LM, Ye M, Vaillancourt P, Dowless M, Stancato LF, Stewart J, Uhlik MT, Long H, Chu S, Obungu VH.

PLoS One. 2016 Mar 8;11(3):e0150585. doi: 10.1371/journal.pone.0150585. eCollection 2016.


A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.


Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS.

Mol Cancer Ther. 2014 Feb;13(2):364-74. doi: 10.1158/1535-7163.MCT-13-0513. Epub 2013 Dec 19.


Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.

Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP.

Blood Cancer J. 2013 Apr 12;3:e109. doi: 10.1038/bcj.2013.6.


Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR.

Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13.


A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.

Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF.

Mol Cancer Ther. 2011 Feb;10(2):242-54. doi: 10.1158/1535-7163.MCT-10-0720. Epub 2011 Jan 7.


eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH.

Cancer Res. 2009 May 1;69(9):3866-73. doi: 10.1158/0008-5472.CAN-08-3472. Epub 2009 Apr 21.


Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG.

J Clin Invest. 2007 Sep;117(9):2638-48.


Inhibitors of cellular signaling targets: designs and limitations.

Vlahos CJ, Stancato LF.

Methods Mol Biol. 2004;273:87-102. Review. No abstract available.


Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity.

Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, Gutkind JS, O'Shea JJ.

Blood. 2000 Sep 1;96(5):1844-52.


Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis.

Wojnowski L, Stancato LF, Larner AC, Rapp UR, Zimmer A.

Mech Dev. 2000 Mar 1;91(1-2):97-104.


Craf-1 protein kinase is essential for mouse development.

Wojnowski L, Stancato LF, Zimmer AM, Hahn H, Beck TW, Larner AC, Rapp UR, Zimmer A.

Mech Dev. 1998 Aug;76(1-2):141-9.


Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor.

Stancato LF, Yu CR, Petricoin EF 3rd, Larner AC.

J Biol Chem. 1998 Jul 24;273(30):18701-4.


Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.

Sakatsume M, Stancato LF, David M, Silvennoinen O, Saharinen P, Pierce J, Larner AC, Finbloom DS.

J Biol Chem. 1998 Jan 30;273(5):3021-6.


Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling.

Petricoin EF 3rd, Ito S, Williams BL, Audet S, Stancato LF, Gamero A, Clouse K, Grimley P, Weiss A, Beeler J, Finbloom DS, Shores EW, Abraham R, Larner AC.

Nature. 1997 Dec 11;390(6660):629-32.


Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.

Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, Krolewski JJ, Silvennoinen O, Saharinen P, Pierce J, Marshall CJ, Sturgill T, Finbloom DS, Larner AC.

Mol Cell Biol. 1997 Jul;17(7):3833-40.


Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants.

Owens-Grillo JK, Stancato LF, Hoffmann K, Pratt WB, Krishna P.

Biochemistry. 1996 Dec 3;35(48):15249-55.


Heat stress protects the perfused rabbit heart from complement-mediated injury.

Gralinski MR, Black SC, Stancato LF, Kilgore KS, Campau PA, Park JL, Ozeck MJ, Pratt WB, Lucchesi BR.

Am J Physiol. 1996 Aug;271(2 Pt 2):H571-8.


Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation.

Stancato LF, David M, Carter-Su C, Larner AC, Pratt WB.

J Biol Chem. 1996 Feb 23;271(8):4134-7.


The native v-Raf.hsp90.p50 heterocomplex contains a novel immunophilin of the FK506 binding class.

Stancato LF, Chow YH, Owens-Grillo JK, Yem AW, Deibel MR Jr, Jove R, Pratt WB.

J Biol Chem. 1994 Sep 2;269(35):22157-61.


Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system.

Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB.

J Biol Chem. 1993 Oct 15;268(29):21711-6.


The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal-binding protein?

Pratt WB, Czar MJ, Stancato LF, Owens JK.

J Steroid Biochem Mol Biol. 1993 Sep;46(3):269-79. Review.


Regulation of glucocorticoid receptor function through assembly of a receptor-heat shock protein complex.

Hutchison KA, Scherrer LC, Czar MJ, Stancato LF, Chow YH, Jove R, Pratt WB.

Ann N Y Acad Sci. 1993 Jun 11;684:35-48. Review.


Differential effects of the reversible thiol-reactive agents arsenite and methyl methanethiosulfonate on steroid binding by the glucocorticoid receptor.

Stancato LF, Hutchison KA, Chakraborti PK, Simons SS Jr, Pratt WB.

Biochemistry. 1993 Apr 13;32(14):3729-36.


Purification of the endogenous glucocorticoid receptor stabilizing factor.

Meshinchi S, Stancato LF, Gordon BM, Jones KW, Pratt WB.

Biochemistry. 1991 Sep 3;30(35):8617-22.


Supplemental Content

Loading ...
Support Center